If AstraZeneca and Bristol Myers Squibb were to successfully become one company, analysts say it could reset the current deal environment, which has picked up greatly in the first half of the year.
News broke over the weekend that Bristol Myers Squibb and AstraZeneca—both massive pharma companies worth more than $130 billion each—have held talks to merge. Analysts largely brushed off the idea as “unlikely,” given the companies have major compet... [3774 chars]